Effective Brief, Low-impact, High-intensity Osteogenic Loading in Postmenopausal Osteoporosis.

Abstract

Background: Osteoporosis is characterized by reduced bone mineral density (BMD) and disrupted microarchitecture estimated by trabecular bone score (TBS), resulting in increased bone fracture risk. "Osteostrong®" is a bone-strengthening system implementing 4 devices and incorporating brief (10-minute), weekly, low-impact, and high-intensity osteogenic loading exercises. We evaluated the efficacy of the Osteostrong® intervention in postmenopausal osteoporotic women.

Methods and subjects: 147 postmenopausal osteoporotic women were separated into two groups: Group A comprised 74 women receiving Osteostrong® intervention (mean age 58.8 years, 56.6-61 years 95% CI), and was subdivided into G1 receiving no antiresorptive medication, and G2 on such medication. Group B comprised 73 women that received no Osteostrong® intervention (mean age 61.8 years, 59.4-64.1 95% CI) and was subdivided into G3 on no antiresorptive therapy, and G4 on such treatment. All participants underwent a physical examination and had an assessment for secondary osteoporosis. Dual-energy X-ray absorptiometry (DXA) examinations (Horizon W [S/N 300472M]) were performed at the time of trial inclusion and 12 months later.

Results: Statistically significant increases were observed in the following parameters: i) BMD of the lumbar spine (L1-L4) in G1(p=0.0039), G2(p<0.001), and G4(p=0.0059): ii) TBS in G2(p=0.0078): iii) BMD of the right femoral neck in G1(p=0.0382) and G4(p=0.032): iv) BMD of the left femoral neck G2(p=0.0089) and in G4(p=0.0498) and total femur in G2(p=0.0162).

Conclusions: Osteostrong® improved BMD of the lumbar spine in women with osteoporosis both off and on antiresorptive treatment. Furthermore, Osteostrong® enhanced the effect of antiresorptive therapy on BMD and TBS of the spine, hip and femoral neck.